GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Aroa Biosurgery Ltd (ASX:ARX) » Definitions » EBIT

Aroa Biosurgery (ASX:ARX) EBIT : A$-8.40 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Aroa Biosurgery EBIT?

Aroa Biosurgery's earnings before interest and taxes (EBIT) for the six months ended in Mar. 2024 was A$-4.65 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was A$-8.40 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Aroa Biosurgery's annualized ROC % for the quarter that ended in Mar. 2024 was -18.90%. Aroa Biosurgery's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -19.77%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Aroa Biosurgery's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -4.36%.

Aroa Biosurgery EBIT Historical Data

The historical data trend for Aroa Biosurgery's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aroa Biosurgery EBIT Chart

Aroa Biosurgery Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24
EBIT
- -16.16 -6.98 -0.35 -8.40

Aroa Biosurgery Semi-Annual Data
Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24
EBIT Get a 7-Day Free Trial -3.01 2.74 -3.10 -3.75 -4.65

Competitive Comparison of Aroa Biosurgery's EBIT

For the Medical Devices subindustry, Aroa Biosurgery's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aroa Biosurgery's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Aroa Biosurgery's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Aroa Biosurgery's EV-to-EBIT falls into.


Aroa Biosurgery EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-8.40 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aroa Biosurgery  (ASX:ARX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Aroa Biosurgery's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=-13.058 * ( 1 - -1.38% )/( (69.372 + 70.719)/ 2 )
=-13.2382004/70.0455
=-18.90 %

where

Invested Capital(Q: Sep. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=104.592 - 2.746 - ( 32.474 - max(0, 8.683 - 68.008+32.474))
=69.372

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=101.878 - 3.432 - ( 27.727 - max(0, 8.728 - 63.329+27.727))
=70.719

Note: The Operating Income data used here is two times the semi-annual (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Aroa Biosurgery's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-9.308/( ( (19.689 + max(28.112, 0)) + (20.38 + max(25.969, 0)) )/ 2 )
=-9.308/( ( 47.801 + 46.349 )/ 2 )
=-9.308/47.075
=-19.77 %

where Working Capital is:

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(16.334 + 6.47 + 13.216) - (2.746 + 0 + 5.162)
=28.112

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(10.5 + 7.434 + 15.842) - (3.432 + 0 + 4.375)
=25.969

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Aroa Biosurgery's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=-8.402/192.503
=-4.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aroa Biosurgery EBIT Related Terms

Thank you for viewing the detailed overview of Aroa Biosurgery's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Aroa Biosurgery (ASX:ARX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Aroa Biosurgery Ltd (ASX:ARX) » Definitions » EBIT
Comparable Companies
ASX:IPD ASX:AVR ASX:CYC ASX:4DX ASX:EMV ASX:IMR ASX:MX1 ASX:SOM ASX:UBI ASX:NTI ABT SYK MDT BSX SZSE:300760 EW DXCM ZBH STE XAMS:PHIA
Traded in Other Exchanges
N/A
Address
64 Richard Pearse Drive, Mangere, Airport Oaks, Auckland, NZL, 2022
Website
https://www.aroabio.com
Aroa Biosurgery Ltd is a soft tissue regeneration company which develops, manufactures and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The Company is in the business of developing, manufacturing and selling soft tissue repair products. The company's principal market is the United States where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery and trauma/limb salvage/tumor surgery.

Aroa Biosurgery (ASX:ARX) Headlines

No Headlines